Evidence map›Paper›PMID 31504643›Full record

ArticleJournal of molecular cell biology2020

Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.

Augustin Le Naour, Mélissa Prat, Benoît Thibault, Renaud Mével, Léa Lemaitre, Hélène Leray, Marie-Véronique Joubert, Kimberley Coulson, Muriel Golzio, Lise Lefevre and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of molecular cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 61 citations in OpenAlex.

  1. The Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Augustin Le NaourInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Mélissa PratUMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, France.
Benoît ThibaultInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Renaud MévelInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Léa LemaitreInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Hélène LerayInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Marie-Véronique JoubertInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Kimberley CoulsonUMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, France.
Muriel GolzioUMR CNRS 5089, Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France.
Lise LefevreUMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, France.
Eliane MeryInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Alejandra MartinezInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Gwénaël FerronInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Jean-Pierre DelordInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Agnès CosteUMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, France.
Bettina CoudercInstitut Claudius Regaud -IUCT Oncopole, Université de Toulouse, Toulouse, France.
Inserm · FRUniversité Toulouse III - Paul Sabatier · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Factors released by surrounding cells such as cancer-associated mesenchymal stromal cells (CA-MSCs) are involved in tumor progression and chemoresistance. In this study, we characterize the mechanisms by which naïve mesenchymal stromal cells (MSCs) can acquire a CA-MSCs phenotype. Ovarian tumor cells trigger the transformation of MSCs to CA-MSCs by expressing pro-tumoral genes implicated in the chemoresistance of cancer cells, resulting in the secretion of high levels of CXC chemokine receptors 1 and 2 (CXCR1/2) ligands such as chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2, and interleukin 8 (IL-8). CXCR1/2 ligands can also inhibit the immune response against ovarian tumor cells. Indeed, through their released factors, CA-MSCs promote the differentiation of monocytes towards M2 macrophages, which favors tumor progression. When CXCR1/2 receptors are inhibited, these CA-MSC-activated macrophages lose their M2 properties and acquire an anti-tumoral phenotype. Both ex vivo and in vivo, we used a CXCR1/2 inhibitor to sensitize ovarian tumor cells to carboplatin and circumvent the pro-tumoral effects of CA-MSCs. Since high concentrations of CXCR1/2 ligands in patients' blood are associated with chemoresistance, CXCR1/2 inhibition could be a potential therapeutic strategy to revert carboplatin resistance.

Indexed as

Cell CommunicationDrug Resistance, NeoplasmAnimalsAntineoplastic AgentsBiomarkersBiopsyCell DifferentiationCell Line, TumorComputational BiologyCytokinesDisease Models, AnimalFemaleGene Expression ProfilingHumansImmunologic FactorsImmunomodulationAntineoplastic AgentsBiomarkersCytokinesImmunologic FactorsReceptors, CXCRchemokineschemoresistancemacrophagesmesenchymal stromal cellsovarian adenocarcinoma

Identifiers

PMID31504643
PMCPMC7181721
OpenAlexW2972265332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.